Navigation Links
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
Date:2/19/2009

Efficacy and Safety Study in Patients with Severe Post-Operative Pain; Data to Serve as Predictor of Clinical Benefits and Support NDA Submission

SYDNEY and BEDMINSTER, N.J., Feb. 19 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today the initiation of a comparative 3-arm pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients who have undergone total knee replacement surgery. Data from this study will be used to further establish the optimal dose regimen for MoxDuo(TM) IR, select an appropriate control group, and properly design an upcoming pivotal Phase 3 trial in patients following total knee replacement surgery. The company expects to complete dosing in April 2009 and is on track to launch MoxDuo(TM) IR in the US marketplace in 2011. Specifically, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US.

"This study represents an important step forward as the data collected will not only provide critical insights for structuring Phase 3 trials leading to product approval, but also serve as an important indicator of the clinical and commercial value MoxDuo(TM) IR offers," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Doctors are looking for new ways to manage the treatment of severe post-operative pain. We anticipate that QRxPharma's patented MoxDuo(TM) IR will greatly improve patient care by providing equal or better analgesia with fewer and less intense side effects than the current standards of care."

In this clinical trial, each group of patients experiencing moderate to severe postoperative pain following total knee r
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... 18, 2014 On Tuesday, Secretary of ... Jim Risch for National Lab Day on the Hill. ... the national laboratory system. Durbin and Risch also formally ... increase awareness of the reach of the national labs ... to address some of our nation's most pressing challenges. ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... Sept. 5 CryoLife, Inc. (NYSE: CRY ... announced,today that D. Ashley Lee, executive vice president, ... Inc., is scheduled to present at,the Bear Stearns ... at 4:30 p.m. EDT. Mr. Lee will also ...
... Medarex, Inc.,(Nasdaq: MEDX ) today announced ... its licensing partner, Centocor R&D, Inc. The,extended relationship ... Antibody Development System(R) for the generation of fully,human ... Under the terms of the new agreement, Centocor ...
... Very Robust Findings on the Key Problems Faced by ... Host a Conference Call Today at 11:00 am CET ... Directly From the Worldsleep07 Congress in,Australia HAMBURG, Germany ... Exchange: EVT),presented today at the worldsleep07 congress in Cairns, ...
Cached Biology Technology:Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening ... a few short months, earning it the first-ever Newborn Screening ... March of Dimes presented Will Humble, M.P.H., Arizona,s Department of ... here today. Mr. Humble established a policy of full transparency ... send newborn blood samples to the lab for analysis, and ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
(Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Dogs can be pessimists too 2Dogs can be pessimists too 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... Santa Barbara have developed new methods for studying how environmental ... spatial and temporal scales. The scientists merged data collected ... canopies taken by the Landsat 5 Thematic Mapper. The findings ... issue of Marine Ecology Progress Series. In ...
... of State Foresters released the first phase of the Southern ... areas forest managers will focus on to maintain southern forests ... urbanization, bioenergy use, weather patterns, land ownership changes and invasive ... 2010 and 2060. About 23 million acres of forest ...
... is available in Spanish . The ... Ikerbasque, is participating in the AWIN -Animal Welfare Indicators project. ... international experts in animal welfare from 11 centres. The group ... University of Edinburgh on the 10 and 11 of May, ...
Cached Biology News:UCSB scientists track environmental influences on giant kelp with help from satellite data 2UCSB scientists track environmental influences on giant kelp with help from satellite data 3Forest Service unveils first comprehensive forecast on southern forests 2Forest Service unveils first comprehensive forecast on southern forests 3Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 2Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 3
Mouse Anti-Human Kallikrein 2 (Hk2)...
... Polyclonal Antibody to Asb-2 (Ankyrin repeat and ... raised against synthetic peptides containing amino acids ... Human spleen lysate (Imgenex Catalog No. 40149) ... It should cross react with mouse and ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
... Neuronal (GLYT2). The antiserum has been tested ... system. The staining pattern obtained with AB1773 ... situ hybridization with probes to GLYT2 mRNA ... glycinergic neurons. Preabsorption of the antiserum with ...
Biology Products: